论文部分内容阅读
目的观察胰岛素泵连续皮下输注(CSII)和多次皮下注射(MSII)治疗方法对初诊2型糖尿病患者胰岛β细胞功能的影响。方法新诊断的2型糖尿病患者(T2DM)60例,分别予以2周的CSII和MSII治疗,检测治疗前后患者的空腹和餐后2h血糖、胰岛素水平以及静脉葡萄糖耐量试验(IVGTT)、得出AIR、Homaβ和Homa IR值,评价两种治疗方法对T2DM患者胰岛β细胞功能的影响。结果 CSII组治疗前后AIR、Homaβ有显著性差异(P<0.01),Homa IR无显著性差异(P>0.05);MSII组治疗前后AIR、Homaβ和Homa IR均无显著性差异(P>0.05);两组治疗前空腹和餐后2 h血糖、胰岛素水平、AIR、Homaβ和Homa IR均无显著性差异(P>0.05);治疗后AIR和Homaβ有显著性差异(P<0.01),Homa IR无显著性差异(P>0.05)。结论 CSII和MSII强化治疗均能很好控制患者血糖水平,但是CSII治疗可以显著改善T2DM患者的胰岛β细胞功能。
Objective To observe the effects of insulin pump continuous subcutaneous infusion (CSII) and multiple subcutaneous injections (MSII) on pancreatic β-cell function in newly diagnosed type 2 diabetic patients. Methods Sixty patients with newly diagnosed type 2 diabetes mellitus (T2DM) were treated with CSII and MSII for 2 weeks. The fasting and postprandial blood glucose, insulin levels and IVGTT were measured before and after treatment. The results showed that AIR , Homaβ and Homa IR values, to evaluate the effect of the two treatment methods on pancreatic β-cell function in T2DM patients. Results Before and after treatment, the levels of AIR and Homaβ in CSII group were significantly different (P <0.01), but there was no significant difference in Homa IR (P> 0.05). There was no significant difference in AIR, Homaβ and Homa IR before and after treatment in CSII group (P> 0.05) ; There was no significant difference in fasting blood glucose, insulin level, AIR, Homaβand Homa IR between the two groups before treatment and 2h after treatment (P> 0.05); Homa IR No significant difference (P> 0.05). Conclusion Both CSII and MSII intensive therapy can well control the blood glucose level of patients, but CSII treatment can significantly improve pancreatic β-cell function in T2DM patients.